BioMarin Pharmaceutical
 
公司簡況
財務
派息紀錄
盈利預測
股權變動
ETF簡況
 
 
 
公司概覽
業務類別 Biotechnology
業務概覽 BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
公司地址 770 Lindaro Street, San Rafael, CA, USA, 94901
電話號碼 +1 415 506-6700
傳真號碼 +1 415 382-7889
公司網頁 https://www.biomarin.com
員工數量 3221
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Ms. Cristin Hubbard Executive Vice President and Chief Commercial Officer 美元 382.85K 08/04/2025
Ms. Rashmi Virendra Ramchandani Vice President and Chief Accounting Officer -- 26/02/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 美元 1.05M 26/02/2026
Mr. G. Eric Davis Executive Vice President, Chief Legal Officer and Secretary 美元 722.12K 08/04/2025
Mr. Brian R. Mueller Executive Vice President, Finance and Chief Financial Officer 美元 699.23K 26/02/2026
Dr. Charles Greg Guyer, PhD Chief Technical Officer and Executive Vice President -- 08/04/2025
Dr. Gregory R. Friberg, M.D. Executive Vice President and Chief Research and Development Officer 美元 161.54K 08/04/2025
 
董事會成員
董事會 職務 更新日期
Mr. Richard A. Meier Chairman of the Board 26/02/2026
Dr. Willard H. Dere, M.D. Independent Director 26/02/2026
Mr. Alexander Hardy Director, President and Chief Executive Officer 26/02/2026
Mr. Robert J. Hombach Independent Director 26/02/2026
Dr. Maykin Ho, PhD Independent Director 26/02/2026
Mr. Ian T. Clark Independent Director 26/02/2026
Ms. Elizabeth McKee Anderson, M.B.A. Independent Director 26/02/2026
Mr. Timothy P. Walbert Independent Director 26/02/2026
Ms. Barbara W. Bodem Independent Director 26/02/2026
Mr. Mark Joseph Enyedy Independent Director 26/02/2026
Dr. Athena Countouriotis, M.D. Independent Director 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 04:30)
代號 名稱 佔比% ▼ 持有日期
INVNAlger Russell Innovation ETF0.002%27/02/2026
NBCRNeuberger Core Equity ETF0.002%28/02/2026
VFMVVanguard US Minimum Volatility ETF0.002%31/12/2025
AVLCAvantis U.S. Large Cap Equity ETF0.002%28/02/2026
DXUVDimensional US Vector Equity ETF0.002%27/02/2026
FLOWGlobal X U.S. Cash Flow Kings 100 ETF0.002%27/02/2026
MIDUDirexion Daily Mid Cap Bull 3X ETF0.002%26/02/2026
DEUSXtrackers Russell US Multifactor ETF0.002%26/02/2026
TMFXMotley Fool Next ETF0.002%27/02/2026
CVLCCalvert US Large-Cp Cor Rspnb ETF0.001%27/02/2026
LRNDNYLI U.S. Large Cap R&D Leaders ETF0.001%27/02/2026
GVUSGoldman Sachs MktBt Russell LgCpValEqETF0.001%27/02/2026
CTRUARK Transparency ETF0.001%30/06/2022
GDVGabelli Dividend & Income0.001%31/12/2025
AVSUAvantis Responsible US Equity ETF0.001%28/02/2026
FNDBSchwab Fundamental U.S. Broad Market ETF0.001%28/02/2026
BMEDiShares Health Innovation Active ETF0.001%26/02/2026
CVMCCalvert US Mid-Cp Cor Rspnb ETF0.001%27/02/2026
VSLUApplied Finance Valuation LgCp ETF0.001%27/02/2026
REVSColumbia Research Enhanced Value ETF0.001%04/02/2026
  1    2    3    4    5   6    7    8    9    10    11  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.